MCID: FLL022
MIFTS: 28

Fallopian Tube Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Clear Cell Adenocarcinoma:

Name: Fallopian Tube Clear Cell Adenocarcinoma 12 15 71
Clear Cell Carcinoma of the Fallopian Tube 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5301
NCIt 49 C6280
UMLS 71 C1333591

Summaries for Fallopian Tube Clear Cell Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Fallopian Tube Clear Cell Adenocarcinoma, also known as clear cell carcinoma of the fallopian tube, is related to fallopian tube carcinoma and adenocarcinoma. An important gene associated with Fallopian Tube Clear Cell Adenocarcinoma is FITM2 (Fat Storage Inducing Transmembrane Protein 2), and among its related pathways/superpathways are Homologous DNA Pairing and Strand Exchange and Integrated Breast Cancer Pathway. The drugs Topotecan and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary and endothelial, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Related Diseases for Fallopian Tube Clear Cell Adenocarcinoma

Diseases related to Fallopian Tube Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 fallopian tube carcinoma 29.9 BRCA2 BRCA1
2 adenocarcinoma 10.2
3 fallopian tube adenocarcinoma 10.2
4 clear cell adenocarcinoma 10.2
5 rare malignant breast tumor 9.8 BRCA2 BRCA1
6 synchronous bilateral breast carcinoma 9.8 BRCA2 BRCA1
7 ovary transitional cell carcinoma 9.8 BRCA2 BRCA1
8 hereditary site-specific ovarian cancer syndrome 9.8 BRCA2 BRCA1
9 familial ovarian cancer 9.8 BRCA2 BRCA1
10 tetraploidy 9.8 BRCA2 BRCA1
11 cancerophobia 9.8 BRCA2 BRCA1
12 basaloid lung carcinoma 9.8 BRCA2 BRCA1
13 nosophobia 9.8 BRCA2 BRCA1
14 breast-ovarian cancer, familial 2 9.8 BRCA2 BRCA1
15 endosalpingiosis 9.8 BRCA2 BRCA1
16 ovarian carcinosarcoma 9.8 BRCA2 BRCA1
17 cervical adenoma malignum 9.8 BRCA2 BRCA1
18 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 9.8 BRCA2 BRCA1
19 mutagen sensitivity 9.8 BRCA2 BRCA1
20 primary peritoneal carcinoma 9.8 BRCA2 BRCA1
21 dysplastic nevus syndrome 9.8 BRCA2 BRCA1
22 breast-ovarian cancer, familial 1 9.8 BRCA2 BRCA1
23 hypertrophy of breast 9.8 BRCA2 BRCA1
24 female reproductive endometrioid cancer 9.8 BRCA2 BRCA1
25 peritoneum cancer 9.8 BRCA2 BRCA1
26 premature menopause 9.8 BRCA2 BRCA1
27 papillary serous adenocarcinoma 9.8 BRCA2 BRCA1
28 lobular neoplasia 9.8 BRCA2 BRCA1
29 fallopian tube disease 9.8 BRCA2 BRCA1
30 thoracic benign neoplasm 9.8 BRCA2 BRCA1
31 fanconi anemia, complementation group d1 9.8 BRCA2 BRCA1
32 myasthenic syndrome, congenital, 6, presynaptic 9.8 BRCA2 BRCA1
33 breast benign neoplasm 9.8 BRCA2 BRCA1
34 fanconi anemia, complementation group j 9.8 BRCA2 BRCA1
35 ovarian cystadenocarcinoma 9.8 BRCA2 BRCA1
36 uterine corpus cancer 9.8 BRCA2 BRCA1
37 papillary adenocarcinoma 9.8 BRCA2 BRCA1
38 bilateral breast cancer 9.8 BRCA2 BRCA1
39 dysgerminoma 9.8 BRCA2 BRCA1
40 female breast cancer 9.8 BRCA2 BRCA1
41 serous cystadenocarcinoma 9.8 BRCA2 BRCA1
42 pre-malignant neoplasm 9.8 BRCA2 BRCA1
43 sporadic breast cancer 9.7 BRCA2 BRCA1
44 in situ carcinoma 9.7 BRCA2 BRCA1
45 breast carcinoma in situ 9.7 BRCA2 BRCA1
46 ovary adenocarcinoma 9.7 BRCA2 BRCA1
47 bloom syndrome 9.7 BRCA2 BRCA1
48 hereditary breast ovarian cancer syndrome 9.7 BRCA2 BRCA1
49 ductal carcinoma in situ 9.7 BRCA2 BRCA1
50 cowden syndrome 1 9.7 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Fallopian Tube Clear Cell Adenocarcinoma:



Diseases related to Fallopian Tube Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 9.86 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 9.86 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 9.86 BRCA1 BRCA2
4 Decreased homologous recombination repair frequency GR00236-A-2 9.86 BRCA1 BRCA2
5 Decreased homologous recombination repair frequency GR00236-A-3 9.86 BRCA1 BRCA2
6 Decreased viability after ionizing radiation GR00232-A-2 9.16 BRCA1 BRCA2
7 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
8 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

Drugs & Therapeutics for Fallopian Tube Clear Cell Adenocarcinoma

Drugs for Fallopian Tube Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Olaparib Approved Phase 3 763113-22-0 23725625
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
9
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
10 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
11
Cediranib Investigational Phase 3 288383-20-0 9933475
12
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
13 Trace Elements Phase 3
14 Carotenoids Phase 3
15 Micronutrients Phase 3
16 topoisomerase I inhibitors Phase 2, Phase 3
17 Albumin-Bound Paclitaxel Phase 3
18 Tubulin Modulators Phase 3
19 Antimitotic Agents Phase 3
20 taxane Phase 3
21 Immunosuppressive Agents Phase 3
22 Protein Kinase Inhibitors Phase 3
23 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
24 Anti-Infective Agents Phase 3
25 Antiviral Agents Phase 3
26 Antimetabolites Phase 3
27
Liposomal doxorubicin Phase 2, Phase 3 31703
28 Anti-Bacterial Agents Phase 2, Phase 3
29 Antibiotics, Antitubercular Phase 2, Phase 3
30 Immunologic Factors Phase 2, Phase 3
31 Immunoglobulins Phase 2, Phase 3
32 Antibodies Phase 2, Phase 3
33 Angiogenesis Inhibitors Phase 2, Phase 3
34 Endothelial Growth Factors Phase 2, Phase 3
35 Immunoglobulins, Intravenous Phase 2, Phase 3
36 Mitogens Phase 2, Phase 3
37 Antibodies, Monoclonal Phase 2, Phase 3
38 Immunoglobulin G Phase 2, Phase 3
39 Antineoplastic Agents, Immunological Phase 2, Phase 3
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
43 Pharmaceutical Solutions Phase 2
44 Alkylating Agents Phase 2
45 Antirheumatic Agents Phase 2
46 Janus Kinase Inhibitors Phase 1, Phase 2
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
48
Propranolol Approved, Investigational Early Phase 1 525-66-6 4946
49
leucovorin Approved Early Phase 1 58-05-9 6006 143
50
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
3 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
4 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
6 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
7 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
8 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
9 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
10 A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib;Ruxolitinib Phosphate
11 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
12 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Ovarian Cancer With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Recruiting NCT04092270 Phase 1 Nedisertib;Pegylated Liposomal Doxorubicin Hydrochloride
13 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Completed NCT01504126 Early Phase 1 Chemotherapy;Propranolol Hydrochloride
14 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1

Search NIH Clinical Center for Fallopian Tube Clear Cell Adenocarcinoma

Genetic Tests for Fallopian Tube Clear Cell Adenocarcinoma

Anatomical Context for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Clear Cell Adenocarcinoma:

40
Ovary, Endothelial

Publications for Fallopian Tube Clear Cell Adenocarcinoma

Articles related to Fallopian Tube Clear Cell Adenocarcinoma:

# Title Authors PMID Year
1
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. 61
26090245 2015

Variations for Fallopian Tube Clear Cell Adenocarcinoma

Expression for Fallopian Tube Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Clear Cell Adenocarcinoma.

Pathways for Fallopian Tube Clear Cell Adenocarcinoma

GO Terms for Fallopian Tube Clear Cell Adenocarcinoma

Cellular components related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA recombination GO:0006310 9.37 BRCA2 BRCA1
2 double-strand break repair via homologous recombination GO:0000724 9.32 BRCA2 BRCA1
3 double-strand break repair GO:0006302 9.26 BRCA2 BRCA1
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.16 BRCA2 BRCA1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 BRCA2 BRCA1
6 chordate embryonic development GO:0043009 8.62 BRCA2 BRCA1

Sources for Fallopian Tube Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....